infectious disease emergency News
-
Enesi Pharma to Present at World Vaccine Congress 2021 Virtual Meeting
Enesi Pharma (“Enesi”), an innovative biotechnology company developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens enabled by its ImplaVax® technologies, announces that its CEO, David Hipkiss will give a presentation at the upcoming World Vaccine Congress 2021 Virtual meeting (4-6 May 2021), which this year is free to attend. ...
-
Enesi Pharma Enters Agreement with National Institutes of Health to Evaluate ImplaVax-enabled Flu Vaccines
Enesi Pharma (“Enesi”), an innovative biotechnology company developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens, enabled by its ImplaVax® technologies, has entered into an agreement with the US National Institute of Health’s (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to test a novel ...
-
Enesi Pharma Achieves Key Milestone in Development of Thermostable Solid-dose Live Vaccines against Measles and Rubella
Enesi Pharma (“Enesi”), an innovative biotechnology company developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens enabled by its ImplaVax® technologies, announces it has achieved a key milestone in its project to develop needle-free thermostable unit solid-dose live vaccines with retained activity against Measles and Rubella. ...
-
Enesi Pharma appoints Elizabeth Eagling-Vose, MBA, as Senior Vice President, Operations
Enesi Pharma Ltd (“Enesi”), an innovative biotechnology company developing next-generation vaccination products, targeting infectious diseases and emergent threat pathogens, enabled by its world leading ImplaVax® technologies, is delighted to announce the appointment of Elizabeth Eagling-Vose, MBA, as Senior Vice President, Operations. Ms. Eagling-Vose brings over 20 years’ ...
-
Grifols Announces Formal Collaboration with US Government to Produce the First Treatment Specifically Targeting COVID-19
Grifols today announces that it has entered into a formal collaboration with the United States Biomedical Advanced Research Development Authority (BARDA), the Food and Drug Administration (FDA) and other Federal public health agencies to collect plasma from convalescent COVID-19 patients, process this specific plasma into a hyperimmune globulin and support the necessary preclinical and clinical ...
-
Enesi Pharma’s ImplaVax-Enabled, Solid-Dose Recombinant Classical Swine Fever (CSF) Vaccine Produces Immune Responses Superior to Liquid Vaccine
Enesi Pharma (“Enesi”), an innovative biotechnology company developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens enabled by its ImplaVax® technologies, is delighted to report positive top-line results from a new study evaluating the immune responses generated by an ImplaVax®-enabled unit solid-dose formulation of classical ...
-
INOVIO Announces First Subject Dosed in Phase 1B Clinical Trial for its DNA Vaccine Against Lassa Fever, INO-4500, in West Africa
INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today announced the first participant was dosed in a Phase 1B clinical trial for INO-4500, its DNA vaccine candidate for Lassa fever, in Ghana. The Phase 1B clinical trial (LSV-002), ongoing at the Noguchi Memorial Institute ...
-
People who have recovered from COVID-19 Can Now Donate their Convalescent Plasma in select Grifols U.S. Plasma Donor Centers
Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company with a track record of more than 100 years and a recognized leader in the development and production of plasma-derived medicines, today announced it has begun identifying, screening and selecting volunteer donors who have recovered from COVID-19 to donate their plasma in select U.S. cities. The plasma will be used to produce ...
-
Enesi Pharma Achieves Preclinical Proof-of-Concept with ImplaVax-Enabled Pandemic Influenza Vaccine
Innovative needle-free injectable unit solid-dose presentation of recombinant H7N9 pandemic flu vaccine, created using Enesi’s ImplaVax technology, generated immune responses comparable with liquid vaccine and demonstrated excellent thermal stability at temperatures up to 40°C for six months. Enesi Pharma (“Enesi”), an innovative biotechnology company developing ...
-
BioLingus to Develop a Sublingual Vaccine for COVID in Cooperation With the Korean CHA Vaccine Institute and PanGen Biotech
Biolingus IP II GmbH and the CHA Vaccine Institute Co., Ltd., with support from the Korean biotech company PanGen Biotech Inc., will collaborate to develop a sublingual vaccine for COVID. The project has received research funding from The Research Investment for Global Health Technology Fund (The RIGHT Fund). The RIGHT Fund is a Public-Private Partnership (PPP) funding agency between the ...
By BioLingus AG
-
As Companies Work Around the Clock to Address COVID-19, BIO Outlines Key Policy Priorities to Prevent the Next Pandemic
The Senate Committee on Health, Education, Labor and Pensions, chaired by Senator Lamar Alexander, will hold an important hearing today to examine lessons learned from the current global health crisis to help make sure we are better prepared for the next pandemic. Public health expert and patient advocate, Dr. Julie Gerberding, will join the discussion, alongside former top policy leaders. The ...
-
N8 Medical Appoints Infectious Diseases Expert, David S. Perlin, Ph.D., to Scientific Advisory Board
N8 Medical, a clinical-stage biopharmaceutical company focused on developing novel combination medical devices and antifungal and anti-bacterial therapeutics for the prevention and treatment of serious and life-threatening infections, announced today that it appointed David S. Perlin, Ph.D. to its Scientific Advisory Board (SAB). Dr. Perlin is an internationally recognized expert and research ...
-
EMLab P&K and Philders Group International Inc. form strategic alliance for infectious disease control initiative
EMLab P&K and Philders Group International Inc. have formed a strategic alliance to create a risk reduction program for the healthcare industry. The Risk Assessment Program (RAP) will address infection control issues encountered in healthcare facilities during construction and will help individuals working in these facilities to reduce risks. The infection control training and education ...
-
CD Genomics Revolutionizes Pathogen Discovery with the Launch of Viral Metagenomic Sequencing Service
CD Genomics, a global leader in genomic and bioinformatics solutions, is pleased to announce the official launch of its Viral Metagenomic Sequencing service. This state-of-the-art offering represents a major advancement in the field of pathogen research and promises to provide unparalleled insights into viral communities. Viruses, being the most abundant entities on our planet, play a pivotal ...
By CD Genomics
-
INOVIO Collaborates with GuardRX and Geneva University Hospitals for Heterologous Booster Clinical Trial of its Ebola DNA Vaccine Candidate, INO-4201
INOVIO (NASDAQ: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced that several volunteers have been dosed with its DNA-based, intradermal Ebola vaccine candidate, INO-4201, as part of a randomized, placebo-controlled, Phase 1b clinical trial ...
-
The Fab’entech biopharmaceutical company Fab’entech is launching the production of its treatment against Ebola.
Recognised for its production capacities, its short development lead times and the quality of its products, Fab’entech has accelerated its project to develop a treatment against Ebola, in collaboration with the World Health Organisation (WHO) and with the support of the European Medicines Agency (EMA). These highly-purified antibodies for use in humans aim to specifically and immediately ...
By Fab’entech
-
Lakhmir Chawla, MD, of Silver Creek Pharmaceuticals Joins ExThera Medical Board of Directors
Professor Lakhmir Chawla, MD, has joined the board of directors of ExThera Medical Corporation, a privately held medical technology company whose Seraph 100 Microbind Affinity Blood Filter is authorized in the United States to treat critically ill COVID-19 patients. Dr. Chawla also serves as the Chair of the Scientific Advisory Board at the company Dr. Chawla is an internationally renowned ...
-
Infection Control Resources to Mitigate Patient Exposure Risks to Klebsiella and Other Pathogens
An article published last year in Emerging Infectious Diseases detailed a notable increase of carbapenem-resistant Klebsiella pneumoniae (CRKP) infections in New York City during 2021 through June of 2022. The data for the study came from a large public healthcare system in New York City that serves more than 1.2 million people each year. The Centers for Disease Control and Prevention (CDC) ...
-
CEPI partners with Japan’s NEC Group to develop artificial intelligence-designed broadly protective betacoronavirus vaccine
April 8, 2022; OSLO, Norway/ TOKYO, Japan: CEPI, the Coalition for Epidemic Preparedness Innovations, and NEC Corporation (NEC: TSE: 6701) today announced the latest funding award under its US$200m programme to advance the development of vaccines that provide broad protection against SARS-CoV-2 variants and other betacoronaviruses[1]. CEPI will provide seed funding of up to US$4.8m to NEC ...
-
Don`t blame the bats
So it seems that COVID-19 may have been transferred to us from bats, via the poor persecuted and endlessly-trafficked pangolin. As well as delaying development by inconveniently occupying land proposed for development, wildlife can now be cast as the villain in the unfolding COVID-19 drama as well. 60% of Emerging Infectious Diseases (EIDs) that affect humans are zoonotic in origin and millions ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you